Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343076 | 0.86 | XIAP (0.44) | HTR7ALDH1A1SMN1; SMN2MAPTXIAP | |
| SCHEMBL9428481 | 0.78 | TSHR (0.46) | HTR7ALDH1A1SMN1; SMN2MAPTXIAP | |
| SCHEMBL8926318 | 0.77 | HTR3A (0.45) | HTR7ALDH1A1SMN1; SMN2XIAPGALR3 | |
| SCHEMBL15565198 | 0.75 | HTR7 (0.40) | HTR7ALDH1A1SMN1; SMN2MAPTXIAP | |
| SCHEMBL8290172 | 0.74 | ESRRA (0.45) | HTR7CYP19A1LOXL2KDM4E | |
| SCHEMBL27715919 | 0.74 | HTR7 (0.48) | HTR7ALDH1A1SMN1; SMN2MAPTXIAP | |
| SCHEMBL9429762 | 0.74 | — | — | |
| SCHEMBL30496165 | 0.73 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTGALR3RAB9A | |
| SCHEMBL483697 | 0.73 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTGALR3RAB9A | |
| SCHEMBL699112 | 0.72 | BIRC5 (0.43) | HTR7TSHRKMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2882725-A1 | SUBSTITUTED HETERO-AZEPINONES | F. Hoffmann-La Roche AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-5374615-A | Treating hypertension and congestive heart failure, preventing cardiac hypertrophy | E. R. SQUIBB & SONS, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| US-5236916-A | Oxadiazinone substituted indole and benzimidazole derivatives | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0488532-A1 | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives | E.R. Squibb & Sons, Inc. (US) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | HTR7 189/4885ALDH1A1 2459/4885SMN1; SMN2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.